| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.74 [0.67, 0.82] | | < 1 | | 52% | 13 studies (13/-) | 100.0 % | low | low | high | crucial | - |
| deaths (OS) (extension) | 0.66 [0.60, 0.73] | | < 1 | | 36% | 6 studies (6/-) | 100.0 % | low | not evaluable | high | important | - |
| MFS | 0.75 [0.65, 0.87] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | low | not evaluable | high | important | - |
| MFS (extension) | 0.76 [0.64, 0.90] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | important | - |
| progression or deaths (PFS) | 0.59 [0.49, 0.72] | | < 1 | | 71% | 7 studies (7/-) | 100.0 % | low | not evaluable | high | important | - |
| RFS (extension) | 0.73 [0.65, 0.83] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | low | not evaluable | high | important | - |
| RFS/DFS | 0.72 [0.62, 0.82] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | low | not evaluable | high | important | - |
| DCR | 1.17 [0.92, 1.50] | | > 1 | | 0% | 2 studies (2/-) | 90.1 % | low | not evaluable | high | non important | - |
| DOR | 0.68 [0.55, 0.85] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 2.84 [1.66, 4.86] | | > 1 | | 90% | 11 studies (11/-) | 100.0 % | low | low | high | non important | - |
safety endpoints 00 |
| AE (any grade) | 2.10 [1.00, 4.39] | | < 1 | | 72% | 7 studies (7/-) | 2.5 % | low | not evaluable | high | non important | - |
| AE (grade 3-4) | 0.78 [0.32, 1.88] | | < 1 | | 98% | 7 studies (7/-) | 71.0 % | low | not evaluable | high | non important | - |
| AE leading to death (grade 5) | 1.68 [0.84, 3.36] | | < 1 | | 0% | 2 studies (2/-) | 7.1 % | some concern | not evaluable | moderate | non important | - |
| AE leading to treatment discontinuation (any grade) | 3.22 [0.01, 1878.15] | | < 1 | | 95% | 2 studies (2/-) | 36.6 % | low | not evaluable | high | non important | - |
| SAE (any grade) | 3.19 [2.19, 4.65] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 1.86 [1.01, 3.42] | | < 1 | | 95% | 12 studies (12/-) | 2.4 % | low | low | high | non important | - |
| TRAE (grade 3-4) | 1.92 [0.90, 4.12] | | < 1 | | 97% | 12 studies (12/-) | 4.7 % | low | low | high | non important | - |
| TRAE leading to death (grade 5) | 1.94 [0.85, 4.40] | | < 1 | | 0% | 9 studies (9/-) | 5.7 % | low | not evaluable | high | non important | - |
| TRAE leading to discontinuation (any grade) | 1.64 [0.52, 5.15] | | < 1 | | 98% | 8 studies (8/-) | 19.9 % | low | not evaluable | high | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 1.00 [0.30, 3.37] | | < 1 | | 96% | 7 studies (7/-) | 50.1 % | low | not evaluable | high | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Adrenal insufficiency TRAE (grade 3-4) | 1.30 [0.55, 3.04] | | < 1 | | 0% | 9 studies (9/-) | 27.4 % | low | not evaluable | high | non important | - |
| Colitis TRAE (grade 3-4) | 1.32 [0.57, 3.09] | | < 1 | | 82% | 11 studies (11/-) | 26.0 % | low | low | high | non important | - |
| Diarrhoea TRAE (grade 3-4) | 1.48 [0.69, 3.17] | | < 1 | | 82% | 12 studies (12/-) | 15.8 % | low | low | high | non important | - |
| Endocrine disorders TRAE (grade 3-4) | 2.62 [0.67, 10.32] | | < 1 | | 74% | 6 studies (6/-) | 8.4 % | low | not evaluable | high | non important | - |
| Eye disorders TRAE (grade 3-4) | 0.66 [0.05, 8.68] | | < 1 | | 0% | 2 studies (2/-) | 62.1 % | low | not evaluable | high | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 3.99 [0.18, 88.89] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Gastrointestinal disorders TRAE (grade 3-4) | 2.23 [0.58, 8.56] | | < 1 | | 94% | 7 studies (7/-) | 12.2 % | low | not evaluable | high | non important | - |
| Guillain-Barré syndrome TRAE (grade 3-4) | 3.99 [0.18, 88.89] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 2.76 [1.23, 6.19] | | < 1 | | 0% | 11 studies (11/-) | 0.7 % | low | low | high | non important | - |
| Hepatobiliary disorders TRAE (grade 3-4) | 1.61 [0.20, 13.18] | | < 1 | | 87% | 6 studies (6/-) | 32.9 % | low | not evaluable | high | non important | - |
| Hypersensitivity TRAE (grade 3-4) | 3.72 [0.39, 35.19] | | < 1 | | 0% | 2 studies (2/-) | 12.8 % | low | not evaluable | high | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.03 [0.29, 3.72] | | < 1 | | 0% | 7 studies (7/-) | 48.0 % | low | not evaluable | high | non important | - |
| Hypophysitis TRAE (grade 3-4) | 0.75 [0.34, 1.65] | | < 1 | | 44% | 11 studies (11/-) | 76.1 % | low | low | high | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 0.94 [0.33, 2.64] | | < 1 | | 0% | 11 studies (11/-) | 55.0 % | low | low | high | non important | - |
| Increase AST TRAE (grade 3-4) | 1.55 [0.40, 6.04] | | < 1 | | 76% | 11 studies (11/-) | 26.5 % | low | low | high | non important | - |
| Increased ALT TRAE (grade 3-4) | 1.85 [0.55, 6.29] | | < 1 | | 81% | 11 studies (11/-) | 16.2 % | low | low | high | non important | - |
| Increased lipase level TRAE (grade 3-4) | 2.09 [1.14, 3.84] | | < 1 | | 19% | 4 studies (4/-) | 0.9 % | low | not evaluable | high | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 3.99 [0.18, 88.89] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 1.25 [0.38, 4.09] | | < 1 | | 22% | 7 studies (7/-) | 35.6 % | low | not evaluable | high | non important | - |
| Nervous system disorders TRAE (grade 3-4) | 12.34 [1.59, 95.62] | | < 1 | | 0% | 2 studies (2/-) | 0.8 % | low | not evaluable | high | non important | - |
| Pancreatitis TRAE (grade 3-4) | 3.68 [0.39, 34.85] | | < 1 | | 0% | 2 studies (2/-) | 13.0 % | some concern | not evaluable | moderate | non important | - |
| Pancytopenia TRAE (grade 3-4) | 1.99 [0.07, 59.56] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Pericarditis TRAE (grade 3-4) | 1.99 [0.07, 59.56] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 3.99 [0.18, 88.89] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 1.57 [0.52, 4.72] | | < 1 | | 0% | 6 studies (6/-) | 21.2 % | low | not evaluable | high | non important | - |
| Polymyalgia Rheumatica TRAE (grade 3-4) | 0.50 [0.02, 14.85] | | < 1 | | 0% | 1 study (1/-) | 65.5 % | NA | not evaluable | | non important | - |
| Pruritic rash TRAE (grade 3-4) | 0.75 [0.16, 3.57] | | < 1 | | 0% | 6 studies (6/-) | 64.1 % | low | not evaluable | high | non important | - |
| Pruritus TRAE (grade 3-4) | 1.28 [0.53, 3.09] | | < 1 | | 0% | 11 studies (11/-) | 28.9 % | low | low | high | non important | - |
| Rash TRAE (grade 3-4) | 1.38 [0.68, 2.82] | | < 1 | | 26% | 12 studies (12/-) | 18.7 % | low | low | high | non important | - |
| Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) | 1.17 [0.13, 10.40] | | < 1 | | 49% | 3 studies (3/-) | 44.6 % | low | not evaluable | high | non important | - |
| Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 2.34 [0.57, 9.58] | | < 1 | | 76% | 7 studies (7/-) | 11.9 % | low | serious | high | non important | - |
| Thyroiditis TRAE (grade 3-4) | 1.49 [0.24, 9.13] | | < 1 | | 0% | 4 studies (4/-) | 33.5 % | low | not evaluable | high | non important | - |
| Uveitis TRAE (grade 3-4) | 0.72 [0.08, 6.18] | | < 1 | | 0% | 3 studies (3/-) | 61.7 % | some concern | not evaluable | moderate | non important | - |
| Vitiligo TRAE (grade 3-4) | 0.74 [0.15, 3.51] | | < 1 | | 0% | 6 studies (6/-) | 64.8 % | low | serious | high | non important | - |
AE (grade 3-4) endpoints 00 |
| Abdominal pain AE (grade 3-4) | 0.43 [0.12, 1.47] | | < 1 | | 79% | 6 studies (6/-) | 91.1 % | low | not evaluable | high | non important | - |
| Anaemia AE (grade 3-4) | 0.44 [0.23, 0.84] | | < 1 | | 12% | 3 studies (3/-) | 99.3 % | low | not evaluable | high | non important | - |
| Asthenia AE (grade 3-4) | 0.14 [0.02, 0.77] | | < 1 | | 0% | 2 studies (2/-) | 98.8 % | low | not evaluable | high | non important | - |
| Chills AE (grade 3-4) | 1.02 [0.02, 51.42] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
| Colitis AE (grade 3-4) | 6.26 [2.61, 15.03] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 0.84 [0.32, 2.18] | | < 1 | | 0% | 5 studies (5/-) | 64.2 % | low | not evaluable | high | non important | - |
| Cough AE (grade 3-4) | 0.43 [0.07, 2.75] | | < 1 | | 45% | 6 studies (6/-) | 81.1 % | low | serious | high | non important | - |
| Decreased appetite AE (grade 3-4) | 0.73 [0.23, 2.34] | | < 1 | | 66% | 6 studies (6/-) | 70.0 % | low | not evaluable | high | non important | - |
| Diarrhoea AE (grade 3-4) | 1.99 [0.45, 8.85] | | < 1 | | 87% | 5 studies (5/-) | 18.5 % | low | serious | high | non important | - |
| Dyspnoea AE (grade 3-4) | 1.34 [0.62, 2.90] | | < 1 | | 40% | 5 studies (5/-) | 22.6 % | low | serious | high | non important | - |
| Fatigue AE (grade 3-4) | 1.03 [0.23, 4.69] | | < 1 | | 95% | 6 studies (6/-) | 48.6 % | low | not evaluable | high | non important | - |
| Headache AE (grade 3-4) | 0.54 [0.12, 2.43] | | < 1 | | 81% | 6 studies (6/-) | 78.6 % | low | serious | high | non important | - |
| Hypophysitis AE (grade 3-4) | 11.01 [2.57, 47.24] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
| Hypothyroidism AE (grade 3-4) | 0.14 [0.02, 1.16] | | < 1 | | 0% | 1 study (1/-) | 96.5 % | NA | not evaluable | | non important | - |
| Increase AST AE (grade 3-4) | 3.68 [0.17, 79.14] | | < 1 | | 95% | 2 studies (2/-) | 20.5 % | low | not evaluable | high | non important | - |
| Increased ALT AE (grade 3-4) | 5.45 [0.16, 182.62] | | < 1 | | 95% | 2 studies (2/-) | 17.6 % | low | not evaluable | high | non important | - |
| Nausea AE (grade 3-4) | 0.53 [0.16, 1.69] | | < 1 | | 76% | 6 studies (6/-) | 85.8 % | low | not evaluable | high | non important | - |
| Neutropenia AE (grade 3-4) | 0.03 [0.00, 0.19] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Peripheral oedema AE (grade 3-4) | 4.97 [0.58, 42.77] | | < 1 | | 0% | 1 study (1/-) | 7.3 % | NA | not evaluable | | non important | - |
| Pruritus AE (grade 3-4) | 1.58 [0.06, 40.78] | | < 1 | | 85% | 3 studies (3/-) | 39.2 % | low | not evaluable | high | non important | - |
| Pyrexia AE (grade 3-4) | 0.46 [0.16, 1.28] | | < 1 | | 22% | 6 studies (6/-) | 93.1 % | low | not evaluable | high | non important | - |
| Rash AE (grade 3-4) | 1.20 [0.03, 47.44] | | < 1 | | 91% | 3 studies (3/-) | 46.2 % | low | not evaluable | high | non important | - |
| Thrombocytopenia AE (grade 3-4) | 0.03 [0.00, 0.26] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 0.76 [0.30, 1.92] | | < 1 | | 68% | 6 studies (6/-) | 71.7 % | low | not evaluable | high | non important | - |
| Weight decreased AE (grade 3-4) | 0.24 [0.02, 3.70] | | < 1 | | 72% | 3 studies (3/-) | 84.4 % | low | not evaluable | high | non important | - |
